New era of antibiotic co-therapy
In today’s world, the overuse of broad-spectrum antibiotics has led to a concerning rise in the prevalence of Multi-Drug Resistant (MDR) pathogens. Shockingly, these resistant strains now account for up to 25% of all identified strains. While antibiotics remain the go-to treatment, their effectiveness is hampered by the dilemma of potential side effects.
Introducing ImmuneBioflora®, a groundbreaking addition to the probiotic market that offers a solution to the challenges of antibiotic co-therapy. In the face of growing antibiotic resistance, we have developed an innovative product that maximizes the benefits of antibiotics while minimizing their adverse effects.
ImmuneBioflora® is meticulously formulated to work in synergy with antibiotics, enhacing their potency and extending their lifespan. By embracing the potential of co-therapy, we address the critical challengue of antibiotic resistance head-on, ensuring that patients receive the most effective treatment available.
ImmuneBioflora® - A new type of antibiotic co-therapy
Our unique combination of natural probiotic strain K12 and Chr. Hansen’s LGG® that reduces respiratory symptoms caused by antibiotic use but also mitigates the side effects associated with their consumption. Furthermore, after antibiotic treatment, helps to restore a protective oral and gut microbiota, promoting overall health and well-being.